{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:08:36Z","timestamp":1795133316170,"version":"4.10.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institutet Research Foundation","award":["2024-02322"],"award-info":[{"award-number":["2024-02322"]}]},{"DOI":"10.13039\/501100006636","name":"Swedish Research Council for Health, Working Life and Welfare","doi-asserted-by":"crossref","award":["2024-01295"],"award-info":[{"award-number":["2024-01295"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2022-01428"],"award-info":[{"award-number":["2022-01428"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2022-01425"],"award-info":[{"award-number":["2022-01425"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"StratNeuro start-up grant"},{"name":"the Center for Innovative Medicine Foundation","award":["FoUI-963369"],"award-info":[{"award-number":["FoUI-963369"]}]},{"name":"\u00c5ke Wibergs stiftelse","award":["M22-0170"],"award-info":[{"award-number":["M22-0170"]}]},{"name":"U&L Angeby stiftelse","award":["2022-02882"],"award-info":[{"award-number":["2022-02882"]}]},{"name":"KI research foundations"},{"DOI":"10.13039\/501100009745","name":"Emil and Wera Cornell Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009745","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Johanniterorden I Sverige\/Swedish Order of St. John, Stiftelsen f\u00f6r Sigurd och Elsa Goljes Minne"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dementia is associated with psychiatric symptoms but the effects of antidepressants on cognitive function in dementia are understudied. We aimed to investigate the association between antidepressants and cognitive decline in patients with dementia, and the risk of severe dementia, fractures and death, depending on antidepressant class, drug, and dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a national cohort study. Patients with dementia registered in the Swedish Registry for Cognitive\/Dementia Disorders-SveDem from May 1, 2007, until October 16, 2018, with at least one follow-up after dementia diagnosis, and who were new users of antidepressants, were included. Antidepressant use as a time varying exposure defined during the 6\u00a0months leading up to dementia diagnosis or each subsequent follow-up. We used linear mixed models to examine the association between antidepressant use and cognitive trajectories assessed by Mini-Mental State Examination (MMSE) scores. We used Cox proportional hazards models to calculate the hazard ratios for severe dementia (MMSE score\u2009&lt;\u200910), fracture, and death. We compared antidepressant classes and drugs, and analyzed dose\u2013response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 18740 patients (10 205 women [54.5%]; mean [SD] age, 78.2[7.4] years), of which 4271 (22.8%) received at least one prescription for an antidepressant. During follow-up, a total of 11912 prescriptions for antidepressants were issued, with selective serotonin reuptake inhibitors (SSRI) being the most common (64.8%). Antidepressant use was associated with faster cognitive decline (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      (95% CI)\u2009= \u2212\u20090.30(\u2212\u20090.39,\u2009\u2212\u20090.21) points\/year), in particular sertraline (\u2212\u20090.25(\u2212\u20090.43,\u2009\u2212\u20090.06) points\/year), citalopram (\u2212\u20090.41(\u2212\u20090.55,\u2009\u2212\u20090.27) points\/year), escitalopram (\u2212\u20090.76(\u2212\u20091.09,\u2009\u2212\u20090.44) points\/year), and mirtazapine (\u2212\u20090.19(\u2212\u20090.34,\u2009\u2212\u20090.04) points\/year) compared with non-use. The association was stronger in patients with severe dementia (initial MMSE scores 0\u20139). Escitalopram showed a greater decline rate than sertraline. Compared with non-use, dose response of SSRIs on greater cognitive decline and higher risks of severe dementia, all-cause mortality, and fracture were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort study, current antidepressant use was associated with faster cognitive decline; furthermore, higher dispensed doses of SSRIs were associated with higher risk for severe dementia, fractures, and all-cause mortality. These findings highlight the significance of careful and regular monitoring to assess the risks and benefits of different antidepressants use in patients with dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-03851-3","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T19:02:51Z","timestamp":1740423771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antidepressant use and cognitive decline in patients with dementia: a national cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Minjia","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Abzhandadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Tuan","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacuiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol Grau","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Naia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna","family":"Kele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Maioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garcia-Ptacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"8","key":"3851_CR1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1176\/appi.ajp.20220508","volume":"179","author":"RR Tampi","year":"2022","unstructured":"Tampi RR, Jeste DV. Dementia Is More Than Memory Loss: Neuropsychiatric Symptoms of Dementia and Their Nonpharmacological and Pharmacological Management. Am J Psychiatry. 2022;179(8):528\u201343.","journal-title":"Am J Psychiatry"},{"key":"3851_CR2","doi-asserted-by":"crossref","unstructured":"Wang GHM, Chen WH, Chang SH, Zhang TX, Shao H, Guo JC, Lo-Ciganic WH. Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study. Bmc Geriatrics. 2023;23(1).","DOI":"10.1186\/s12877-023-04475-z"},{"key":"3851_CR3","doi-asserted-by":"crossref","unstructured":"Blumberg MJ, Vaccarino SR, McInerney SJ. Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review. J Clin Psychiatry. 2020;81(4).","DOI":"10.4088\/JCP.19r13200"},{"issue":"36","key":"3851_CR4","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","volume":"108","author":"JR Cirrito","year":"2011","unstructured":"Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108(36):14968\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"236","key":"3851_CR5","doi-asserted-by":"crossref","first-page":"236re4","DOI":"10.1126\/scitranslmed.3008169","volume":"6","author":"YI Sheline","year":"2014","unstructured":"Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4.","journal-title":"Sci Transl Med."},{"issue":"6","key":"3851_CR6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/gps.4375","volume":"31","author":"GH Pelton","year":"2016","unstructured":"Pelton GH, Harper OL, Roose SP, Marder K, D\u2019Antonio K, Devanand DP. Combined treatment with memantine\/es-citalopram for older depressed patients with cognitive impairment: a pilot study. Int J Geriatr Psychiatry. 2016;31(6):648\u201355.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"3851_CR7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","volume":"175","author":"C Bartels","year":"2018","unstructured":"Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. Alzheimer\u2019s Disease Neuroimaging I. Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer\u2019s Dementia in Individuals With Previous Depression. Am J Psychiatry. 2018;175(3):232\u201341.","journal-title":"Am J Psychiatry."},{"key":"3851_CR8","unstructured":"committee RSsm. KLOKA LISTAN 2024. Stockholm, Sweden: Stockholm County Council; 2024. Available from: https:\/\/klokalistan.se\/download\/18.2eb60b5b18d2a87a7321b413\/1706013022004\/Kloka_Listan_2024_webb_20240123.pdf.\u00a0Cited 2024 03 March."},{"issue":"10","key":"3851_CR9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.2018.11154","volume":"320","author":"R Rubin","year":"2018","unstructured":"Rubin R. Exploring the Relationship Between Depression and Dementia. JAMA. 2018;320(10):961\u20132.","journal-title":"JAMA"},{"issue":"6","key":"3851_CR10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jgs.12838","volume":"62","author":"SK Dutcher","year":"2014","unstructured":"Dutcher SK, Rattinger GB, Langenberg P, Chhabra PT, Liu X, Rosenberg PB, et al. Effect of medications on physical function and cognition in nursing home residents with dementia. J Am Geriatr Soc. 2014;62(6):1046\u201355.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3851_CR11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1017\/S1041610209990184","volume":"22","author":"L Rozzini","year":"2010","unstructured":"Rozzini L, Chilovi BV, Conti M, Bertoletti E, Zanetti M, Trabucchi M, Padovani A. Efficacy of SSRIs on cognition of Alzheimer\u2019s disease patients treated with cholinesterase inhibitors. Int Psychogeriatr. 2010;22(1):114\u20139.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"3851_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12916-017-0847-z","volume":"15","author":"I Carriere","year":"2017","unstructured":"Carriere I, Norton J, Farre A, Wyart M, Tzourio C, Noize P, et al. Antidepressant use and cognitive decline in community-dwelling elderly people - The Three-City Cohort. BMC Med. 2017;15(1):81.","journal-title":"BMC Med"},{"issue":"6","key":"3851_CR13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2710.2006.00778.x","volume":"31","author":"J Caballero","year":"2006","unstructured":"Caballero J, Hitchcock M, Beversdorf D, Scharre D, Nahata M. Long-term effects of antidepressants on cognition in patients with Alzheimer\u2019s disease. J Clin Pharm Ther. 2006;31(6):593\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"3851_CR14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.amjmed.2015.01.007","volume":"128","author":"JS Saczynski","year":"2015","unstructured":"Saczynski JS, Rosen AB, McCammon RJ, Zivin K, Andrade SE, Langa KM, et al. Antidepressant Use and Cognitive Decline: The Health and Retirement Study. Am J Med. 2015;128(7):739\u201346.","journal-title":"Am J Med"},{"issue":"5","key":"3851_CR15","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/alz.13807","volume":"20","author":"I Vom Hofe","year":"2024","unstructured":"Vom Hofe I, Stricker BH, Vernooij MW, Ikram MK, Ikram MA, Wolters FJ. Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy. Alzheimers Dement. 2024;20(5):3378\u201387.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"3851_CR16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1017\/S1041610211002778","volume":"24","author":"JS Goveas","year":"2012","unstructured":"Goveas JS, Hogan PE, Kotchen JM, Smoller JW, Denburg NL, Manson JE, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women\u2019s Health Initiative Memory Study. Int Psychogeriatr. 2012;24(8):1252\u201364.","journal-title":"Int Psychogeriatr"},{"issue":"12","key":"3851_CR17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/gps.3769","volume":"27","author":"PB Rosenberg","year":"2012","unstructured":"Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2012;27(12):1248\u201357.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"3851_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0891988716654985","volume":"29","author":"S Garcia-Ptacek","year":"2016","unstructured":"Garcia-Ptacek S, Kramberger MG. Parkinson Disease and Dementia. J Geriatr Psych Neur. 2016;29(5):261\u201370.","journal-title":"J Geriatr Psych Neur"},{"issue":"12","key":"3851_CR19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","volume":"60","author":"NI Bohnen","year":"2003","unstructured":"Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease - An in vivo positron emission tomographic study. Arch Neurol-Chicago. 2003;60(12):1745\u20138.","journal-title":"Arch Neurol-Chicago"},{"issue":"2","key":"3851_CR20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JAD-180353","volume":"65","author":"ECK Tan","year":"2018","unstructured":"Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic Burden and Risk of Stroke and Death in People with Different Types of Dementia. Journal of Alzheimers Disease. 2018;65(2):589\u201396.","journal-title":"Journal of Alzheimers Disease"},{"key":"3851_CR21","first-page":"411","volume":"9","author":"X Liu","year":"2014","unstructured":"Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Clin Interv Aging. 2014;9:411\u20138.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"3851_CR22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004;172(4):400\u20138.","journal-title":"Psychopharmacology"},{"issue":"4","key":"3851_CR23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/WAD.0b013e3181e6a4d7","volume":"24","author":"S Culo","year":"2010","unstructured":"Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Pollock BG. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24(4):360\u20134.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9427","key":"3851_CR24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","volume":"363","author":"C Courtney","year":"2004","unstructured":"Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105\u201315.","journal-title":"Lancet"},{"issue":"2","key":"3851_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116538","volume":"10","author":"D Religa","year":"2015","unstructured":"Religa D, Fereshtehnejad SM, Cermakova P, Edlund AK, Garcia-Ptacek S, Granqvist N, et al. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS ONE. 2015;10(2): e0116538.","journal-title":"PLoS ONE"},{"key":"3851_CR26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"issue":"7","key":"3851_CR27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3851_CR28","unstructured":"(Socialstyrelsen). NBoHaW. D\u00f6dsorsaksregistret Sweden: National Board of Health and Welfare (Socialstyrelsen); 2023. Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/dodsorsaksregistret\/."},{"key":"3851_CR29","volume-title":"The ICD-10 classification of mental and behavioural disorders, clinical descriptions and diagnostic guidelines","author":"WH Organization","year":"1992","unstructured":"Organization WH. The ICD-10 classification of mental and behavioural disorders, clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992."},{"issue":"8","key":"3851_CR30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00406-009-0008-2","volume":"259","author":"A Castagnini","year":"2009","unstructured":"Castagnini A, Berrios GE. Acute and transient psychotic disorders (ICD-10 F23): a review from a European perspective. Eur Arch Psychiatry Clin Neurosci. 2009;259(8):433\u201343.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3851_CR31","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-IV)","author":"AP Association","year":"1994","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4"},{"issue":"1","key":"3851_CR32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S0033291700011016","volume":"19","author":"RE Kendell","year":"1989","unstructured":"Kendell RE. Clinical validity. Psychol Med. 1989;19(1):45\u201355.","journal-title":"Psychol Med"},{"key":"3851_CR33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/NDT.S45840","volume":"9","author":"SM Fereshtehnejad","year":"2013","unstructured":"Fereshtehnejad SM, Religa D, Westman E, Aarsland D, Lokk J, Eriksdotter M. Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson\u2019s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). Neuropsychiatr Dis Treat. 2013;9:927\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3851_CR34","doi-asserted-by":"crossref","unstructured":"Ballard C, Garcia-Ptacek S, van Steenoven I, Aarsland D. 241Spectrum of Lewy body dementias: relationship of Parkinson\u2019s disease dementia to dementia with Lewy bodies. In: Emre M, editor. Cognitive Impairment and Dementia in Parkinson's Disease: Oxford University Press; 2015. p. 0.","DOI":"10.1093\/med\/9780199681648.003.0018"},{"key":"3851_CR35","unstructured":"Organization WH. Defined Daily Dose: Essential Medicines and Health Products: ATC\/DDD Toolkit: World Health Organization. Available from: https:\/\/www.who.int\/toolkits\/atc-ddd-toolkit\/about-ddd."},{"issue":"17","key":"3851_CR36","first-page":"e2220","volume":"96","author":"H Xu","year":"2021","unstructured":"Xu H, Garcia-Ptacek S, Jonsson L, Wimo A, Nordstrom P, Eriksdotter M. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology. 2021;96(17):e2220\u201330.","journal-title":"Neurology"},{"key":"3851_CR37","unstructured":"Dementia: Assessment, management and support for people living with dementia and their carers. National Institute for Health and Care Excellence: Guidelines. London 2018."},{"issue":"5","key":"3851_CR38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"3851_CR39","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"5","key":"3851_CR40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/alz.12050","volume":"16","author":"R Handels","year":"2020","unstructured":"Handels R, Jonsson L, Garcia-Ptacek S, Eriksdotter M, Wimo A. Controlling for selective dropout in longitudinal dementia data: Application to the SveDem registry. Alzheimers Dement. 2020;16(5):789\u201396.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"3851_CR41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","volume":"7","author":"AL Byers","year":"2011","unstructured":"Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7(6):323\u201331.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"3851_CR42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1192\/bjp.bp.112.118307","volume":"202","author":"BS Diniz","year":"2013","unstructured":"Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer\u2019s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329\u201335.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"3851_CR43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391.","journal-title":"JAMA"},{"issue":"8","key":"3851_CR44","first-page":"CD003944","volume":"8","author":"R Dudas","year":"2018","unstructured":"Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018;8(8):CD003944.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"3851_CR45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6027","volume":"3","author":"F Maier","year":"2020","unstructured":"Maier F, Spottke A, Bach JP, Bartels C, Buerger K, Dodel R, et al. Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(5): e206027.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3851_CR46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/jcp.0b013e31814b98c1","volume":"27","author":"A Mowla","year":"2007","unstructured":"Mowla A, Mosavinasab M, Haghshenas H, Borhani HA. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer\u2019s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007;27(5):484\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"3851_CR47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jpsychires.2022.09.039","volume":"155","author":"M Qin","year":"2022","unstructured":"Qin M, Wu J, Zhou Q, Liang Z, Su Y. Global cognitive effects of second-generation antidepressants in patients with Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2022;155:371\u20139.","journal-title":"J Psychiatr Res"},{"issue":"9","key":"3851_CR48","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","volume":"55","author":"L Teri","year":"2000","unstructured":"Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271\u20138.","journal-title":"Neurology"},{"issue":"7","key":"3851_CR49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/gps.4384","volume":"31","author":"YM Choe","year":"2016","unstructured":"Choe YM, Kim KW, Jhoo JH, Ryu SH, Seo EH, Sohn BK, et al. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2016;31(7):731\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"3851_CR50","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JGP.0b013e31826ce4c5","volume":"20","author":"CA Munro","year":"2012","unstructured":"Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, et al. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012;20(12):1036\u201344.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"3851_CR51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","volume":"149","author":"G Gartlehner","year":"2008","unstructured":"Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734\u201350.","journal-title":"Ann Intern Med"},{"issue":"10128","key":"3851_CR52","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366.","journal-title":"Lancet"},{"key":"3851_CR53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","volume":"5","author":"JS Andrews","year":"2019","unstructured":"Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials. Alzheimers Dement (N Y). 2019;5:354\u201363.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"14","key":"3851_CR54","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1017\/S0033291715001075","volume":"45","author":"GS Alexopoulos","year":"2015","unstructured":"Alexopoulos GS, Manning K, Kanellopoulos D, McGovern A, Seirup JK, Banerjee S, Gunning F. Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant. Psychol Med. 2015;45(14):3111\u201320.","journal-title":"Psychol Med"},{"key":"3851_CR55","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/NDT.S334647","volume":"17","author":"L Zhang","year":"2021","unstructured":"Zhang L, Liu X, Li T, Xu B, Fu B. Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study. Neuropsychiatr Dis Treat. 2021;17:3819\u201325.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Pt 7","key":"3851_CR56","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/brain\/awv133","volume":"138","author":"LE Hughes","year":"2015","unstructured":"Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138(Pt 7):1961\u201375.","journal-title":"Brain"},{"issue":"10","key":"3851_CR57","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00002512-200825100-00006","volume":"25","author":"K Johnell","year":"2008","unstructured":"Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging. 2008;25(10):871\u20137.","journal-title":"Drugs Aging"},{"issue":"2","key":"3851_CR58","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jagp.2019.08.011","volume":"28","author":"H Lavretsky","year":"2020","unstructured":"Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda A, et al. A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. Am J Geriat Psychiat. 2020;28(2):178\u201390.","journal-title":"Am J Geriat Psychiat"},{"key":"3851_CR59","first-page":"204062231985371","volume":"10","author":"JA Su","year":"2019","unstructured":"Su JA, Chang CC, Wang HM, Chen KJ, Yang YH, Lin CY. Antidepressant treatment and mortality risk in patients with dementia and depression: a nationwide population cohort study in Taiwan. Ther Adv Chronic Dis. 2019;10:2040622319853719.","journal-title":"Ther Adv Chronic Dis"},{"issue":"5","key":"3851_CR60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/acps.12630","volume":"134","author":"D Enache","year":"2016","unstructured":"Enache D, Fereshtehnejad SM, Kareholt I, Cermakova P, Garcia-Ptacek S, Johnell K, et al. Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. Acta Psychiatr Scand. 2016;134(5):430\u201340.","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"3851_CR61","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/gps.5587","volume":"36","author":"JK Zakarias","year":"2021","unstructured":"Zakarias JK, Norgaard A, Jensen-Dahm C, Gasse C, Laursen TM, Palm H, et al. Risk of hospitalization and hip fracture associated with psychotropic polypharmacy in patients with dementia: A nationwide register-based study. Int J Geriatr Psychiatry. 2021;36(11):1691\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"3851_CR62","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ageing\/aft009","volume":"42","author":"MS Bakken","year":"2013","unstructured":"Bakken MS, Engeland A, Engesaeter LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing. 2013;42(4):514\u201320.","journal-title":"Age Ageing"},{"key":"3851_CR63","unstructured":"SveDem. Svenska Demensregistret \u00c5rsrapport 2022 Sweden2022. Available from: https:\/\/www.ucr.uu.se\/svedem\/om-svedem\/arsrapporter\/svedemarsrapport-2022\/viewdocument\/1077.\u00a0Cited 2023 Oct 18."},{"issue":"10","key":"3851_CR64","volume":"6","author":"M Mo","year":"2023","unstructured":"Mo M, Zacarias-Pons L, Hoang MT, Mostafaei S, Jurado PG, Stark I, et al. Psychiatric Disorders Before and After Dementia Diagnosis. JAMA Netw Open. 2023;6(10): e2338080.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3851_CR65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3233\/JAD-131856","volume":"41","author":"S Garcia-Ptacek","year":"2014","unstructured":"Garcia-Ptacek S, Farahmand B, Kareholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467\u201377.","journal-title":"J Alzheimers Dis"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03851-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03851-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03851-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T19:03:29Z","timestamp":1740423809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03851-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3851"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03851-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement of written consent for this study was waived due to the register data being pseudonymized before delivery to our research group. The regional ethics committee in Stockholm approved the study (dnr 2017\/501\u201331; 2017\/942\u201332), which complies with the Declaration of Helsinki 31. Participants and caretakers are informed verbally about SveDem and could decline participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}